Approval and Launch of New Products and High Prevalence of Cancer to Augment Growth of Opioid Induced Constipation Treatment Market

 

Opioid-induced constipation (OIC) is caused by prolonged use of certain opioids, particularly for pain management. OIC may also be caused by taking long-term and excessive doses of narcotics with effects similar to dehydration, constipation, or nausea. OIC is a common condition affecting individuals with long-standing or steady use of powerful prescription pain medications like OxyContin, codeine and morphine, as well as individuals who take sedatives frequently or individuals who have other conditions like diarrhea, kidney or liver disease, or Crohn's disease.

Market Dynamics

Approval and launch of new products is expected to propel growth of the Opioid Induced Constipation Treatment Market. For instance, in September 2020, Sandoz, the generics division of Novartis AG, received a positive reimbursement decision in the UK for Rizmoic (naldemedine). The National Institute for Health and Care Excellence, U.K., issued a recommendation in favor of the option for treating opioid-induced constipation in adults, after previous laxative treatment. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

The Opioid Induced Constipation Treatment Market is witnessing launch of generic products. For instance, in January 2021, Par Pharmaceutical, Inc. launched the first authorized generic version of Amitiza, indicated for the treatment of chronic idiopathic constipation and opioid-induced constipation in adult with chronic non-cancer pain.

Decrease in opioid prescribing rates is expected to hinder growth of the Opioid Induced Constipation Treatment Market. For instance, according to the Centers for Disease Control and Prevention’s surveillance summaries published in January 2020, in the U.S. opioid prescribing rates declined in all 11 states during 2010–2016 (range: 14.9% to 33.0%).

The opioid-induced constipation treatment is witnessing several divesture activities. For instance, in February 2020, AstraZeneca agreed to sublicense its global rights to Movantik (naloxegol), a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of OIC, excluding Europe, Canada and Israel, to RedHill Biopharma.

Competitive Analysis

Major players operating in the Opioid Induced Constipation Treatment Market include, Daewoong Co. Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Cosmo Pharmaceuticals, AstraZeneca plc, Shionogi Inc., Abbott Laboratories, Valeant Pharmaceuticals, C.B. Fleet Company, Inc., and Bayer AG.

Major players operating in the Opioid Induced Constipation Treatment Market are focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in April 2019, BioDelivery Sciences, a Raleigh-based pharmaceutical company, acquired exclusive rights to commercialize an opioid-induced constipation drug in the U.S and Puerto Rico under a deal with Shinogi.